Orexo Enters into an Agreement with GAIA to Develop and Commercialize Digital Therapy for Opioid Use Disorder
Shots:
- GAIA to receive royalties- milestone and financial compensation during the development phase. Orexo to get exclusive WW rights to commercialize DTx (OXD-01) and is responsible for the clinical development- regulatory approval and commercialization activities
- The DTx is based on GAIA’s Broca technology platform which is an AI-expert system that engaged users in personalized and simulated 1:1 interaction and guiding patients step-by-step to achieve therapeutic target
- OXD-01 is a fully automated DTx based on GAIA’s Broca platform having an ability to run DTx on nearly all web compatible devices- including virtual reality applications and intended to use for the treatment of OUD with its anticipated launch in 2022 in the US
Click here to read full press release/ article | Ref: PRNewswire | Image: The Pharma Letter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
